Mouse Anti-Human Fibromodulin
Product number PDZMM121
Host species Mouse
Target species Human
Suitable for: IHC-P, WB, ELISA, Immunomicroscopy, Dot blot, ICC, IHC-Fr
Immunogen A KLH-conjugated synthetic peptide derived from human Fibromodulin protein was used for immunization.
Storage instructions Shipped at 4 °C. Store at -20 °C. Avoid freeze/thaw cycle. Please see notes section.
Storage buffer Phosphate buffered saline pH 7.4, contains stabilizer and ≤0.09% sodium azide.
Purity Immunogen affinity purified
Purification notes This product was prepared by immunoaffinity chromatography using immunogen peptide coupled to Sepharose 4B.
Conjugation notes –
General notes For extended storage aliquot contents and freeze at -20 °C or below. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4 °C as an undiluted liquid. Dilute only prior to immediate use.
Our customer’s feedback says the antibody worked great. If in case the antibody fails to give results then please contact our scientific support team for assistance.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end-user.
Product Usage Information:
Western Blotting 3-5 ug/ml
Immunohistochemistry (Paraffin) 5-10 ug/ml
Immunohistochemistry (Frozen) 5-10 ug/ml
Immunofluorescence 5-10 ug/ml
Flow Cytometry 5-10 ug/ml
Please note: All products are “FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES”
Fibromodulin is a protein that in humans is encoded by the FMOD gene.
Fibromodulin is a 42kDa protein of a family of small interstitial leucine-rich repeat proteoglycans (SLRPs). It can have up to four N-linked keratan sulfate chains attached to the core protein within the leucine-rich region. It shares significant sequence homology with biglycan and decorin.
The product has been utilized in:
Farahi L, Ghaemimanesh F, Milani S, Razavi SM, Hadavi R, Bayat AA, Salimi A, Akhondi MM, Rabbani H. GPI-anchored fibromodulin as a novel target in chronic lymphocytic leukemia: diagnostic and therapeutic implications. Iranian Journal of Immunology. 2019 Jun 1;16(2):127-41.
Note: This product has originally been developed at Avicenna Research Institute, Tehran, IRAN and assigned to PADZA Company according to contract 98/15/191dated 98/01/10.